MULTI-018 Larotrectinib v1
MULTI-019 Entrectinib v1
BRE-002 Capecitabine v5
BRE-032 Pertuzumab, trastuzumab and docetaxel for locally advanced or metastatic breast cancer v8
BRE-037 Trastuzumab Emtansine (Kadcyla®) MBC v4
BRE-058 EC for Breast Cancer v2
BRE-059 EC followed by Carboplatin & Paclitaxel for Breast Cancer v4
BRE-060 FEC-T plus trastuzumab & pertuzumab (neoadjuvant) v3
BRE-061 TCH-P (neoadjuvant) v3
BRE-062 Palbociclib with Letrozole v4
BRE-063 Ribociclib with an Aromatase Inhibitor v1
BRE-065 FEC-T plus trastuzumab & pertuzumab (adjuvant) v1
BRE-066 TCH-P (adjuvant) v1
BRE-067 Atezolizumab in combination with nab-paclitaxel v2
BRE-068 Abemaciclib and Fulvestrant v1
BRE-069 EC followed by Paclitaxel, Pertuzumab and Trastuzumab IV (Ontruzant®) adjuvant v1
BRE-071 Neratinib v1
BRE-072 Ribociclib and Fulvestrant v1
BRE-073 Palbociclib and fulvestrant v1
BRE-075 Trastuzumab emtansine (Kadcyla®) EBC adjuvant v1
BRE-081 EC followed by paclitaxel (weekly) & Phesgo® (pertuzumab/trastuzumab SC) Adjuvant v1
